PMID- 33574700
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by 
      Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas.
PG  - 1009-1016
LID - 10.2147/CMAR.S286322 [doi]
AB  - PURPOSE: Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor 
      activity in patients with advanced soft tissue sarcomas (STS) in China. Liposomal 
      doxorubicin monotherapy showed an encouraging effect on this disease. The aim of 
      this study was to evaluate the efficacy and safety of anlotinib combined with 
      liposomal doxorubicin followed by anlotinib maintenance in patients with 
      metastatic STS. PATIENTS AND METHODS: This is a multicenter, retrospective, 
      observational study. We reviewed 27 patients with metastatic STS from July 2018 
      to December 2019, who were treated with anlotinib combined with liposomal 
      doxorubicin followed by anlotinib maintenance in the absence of the tumor 
      progression or intolerable adverse events (AEs). RESULTS: Of the 27 patients 
      included, 2 patients had complete response (CR), 9 patients obtained partial 
      response (PR), 11 patients achieved stable disease (SD). The objective response 
      rate was 40.7%, the disease control rate was 81.5%, and the median 
      progression-free survival (PFS) was 7 months (95% CI, 5.3-8.1 months). The 
      progression-free rate (PFR) at 3 and 6 months was 81.5% and 59.3%, respectively. 
      Most AEs were mild and acceptable. The most frequent grade 3/4 AEs were 
      leukopenia (33.3%), febrile neutropenia (7.4%), and anemia (7.4%). No deaths 
      related to the treatment were reported. CONCLUSION: This study shows that 
      anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance 
      is effective in patients with metastatic STS, and most AEs of this combined 
      therapy are mild and acceptable. Further investigation on its efficacy is 
      warranted.
CI  - (c) 2021 Liu et al.
FAU - Liu, Zhiyong
AU  - Liu Z
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
FAU - Yao, Weitao
AU  - Yao W
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
FAU - Zhao, Yao
AU  - Zhao Y
AD  - Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, Henan, People's Republic of China.
FAU - Liu, Oufei
AU  - Liu O
AD  - Department of Oncology, The Fifth Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, Henan, People's Republic of China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
FAU - Ge, Hong
AU  - Ge H
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University and Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210204
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7871875
OTO - NOTNLM
OT  - anlotinib
OT  - efficacy
OT  - liposomal doxorubicin
OT  - safety
OT  - soft tissue sarcomas
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/02/13 06:00
MHDA- 2021/02/13 06:01
PMCR- 2021/02/04
CRDT- 2021/02/12 06:07
PHST- 2020/10/12 00:00 [received]
PHST- 2021/01/05 00:00 [accepted]
PHST- 2021/02/12 06:07 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/02/13 06:01 [medline]
PHST- 2021/02/04 00:00 [pmc-release]
AID - 286322 [pii]
AID - 10.2147/CMAR.S286322 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Feb 4;13:1009-1016. doi: 10.2147/CMAR.S286322. eCollection 
      2021.